ENZN - Enzon Pharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.261
+0.001 (+0.385%)
At close: 3:32PM EDT
Stock chart is not supported by your current browser
Previous Close0.260
Open0.260
Bid0.380 x 3000
Ask1.410 x 200
Day's Range0.260 - 0.265
52 Week Range0.030 - 0.350
Volume9,500
Avg. Volume117,733
Market Cap11.54M
Beta-0.57
PE Ratio (TTM)2.18
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2015-12-30
1y Target EstN/A
Trade prices are not sourced from all markets
  • Enzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 18, 2017
    Capital Cube11 months ago

    Enzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 18, 2017

    Categories: Yahoo FinanceGet free summary analysis Enzon Pharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Enzon Pharmaceuticals, Inc. – Nektar Therapeutics, Amgen Inc., Enanta Pharmaceuticals, Inc., Pfizer Inc., Merck & Co., Inc., Valeant Pharmaceuticals International Inc, XOMA Corporation, SciClone Pharmaceuticals, Inc., Gilead Sciences, ... Read more (Read more...)

  • We're sorry this is all we were able to find about this topic.